Sign in

CIK 0001404644

  • Non-accelerated filer
  • Smaller reporting company

Neurogene Inc.

Sign in to watch
Ticker
NGNE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
980542593
Phone
+1 877-237-5020
Business address
535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
Former names
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2022-02-01 Ho Robert Chief Financial Officer Grant or award · Restricted Stock Units +70,000 70,000
2021-08-03 Ho Robert Chief Financial Officer Grant or award · Stock Option (Right to Buy) +190,000 190,000
2021-03-17 Ho Robert Chief Financial Officer Sale −6,497 $11.01 $72K 21,503
2021-03-16 Ho Robert Chief Financial Officer Option exercise +25,000 28,000
2021-03-16 Ho Robert Chief Financial Officer Option exercise · Restricted Stock Units +25,000 50,000
2020-08-10 Ho Robert Chief Financial Officer Grant or award · Stock Option (Right to Buy) +90,000 90,000
2020-03-16 Ho Robert Chief Financial Officer Grant or award · Restricted Stock Units +75,000 75,000
2020-03-16 Ho Robert Chief Financial Officer Grant or award · Stock Option (Right to Buy) +200,000 200,000

Page 1 of 1 · 8 trades